Imaging Techniques in Alzheimer’s Disease: A Review of Applications in Early Diagnosis and Longitudinal Monitoring
Open accessThe DOI matches its Crossref record; 228 of the 232 references it cites were found in a registry or an index.
Abstract
Background. Alzheimer’s disease (AD) is a progressive neurodegenerative disorder affecting many individuals worldwide with no effective treatment to date. AD is characterized by the formation of senile plaques and neurofibrillary tangles, followed by neurodegeneration, which leads to cognitive decline and eventually death. Introduction. In AD, pathological changes occur many years before disease onset. Since disease-modifying therapies may be the most beneficial in the early stages of AD, biomarkers for the early diagnosis and longitudinal monitoring of disease progression are essential. Multiple imaging techniques with associated biomarkers are used to identify and monitor AD. Aim. In this review, we discuss the contemporary early diagnosis and longitudinal monitoring of AD with imaging techniques regarding their diagnostic utility, benefits and limitations. Additionally, novel techniques, applications and biomarkers for AD research are assessed. Findings. Reduced hippocampal volume is a biomarker for neurodegeneration, but atrophy is not an AD-specific measure. Hypometabolism in temporoparietal regions is seen as a biomarker for AD. However, glucose uptake reflects astrocyte function rather than neuronal function. Amyloid-β (Aβ) is the earliest hallmark of AD and can be measured with positron emission tomography (PET), but Aβ accumulation stagnates as disease progresses. Therefore, Aβ may not be a suitable biomarker for monitoring disease progression. The measurement of tau accumulation with PET radiotracers exhibited promising results in both early diagnosis and longitudinal monitoring, but large-scale validation of these radiotracers is required. The implementation of new processing techniques, applications of other imaging techniques and novel biomarkers can contribute to understanding AD and finding a cure. Conclusions. Several biomarkers are proposed for the early diagnosis and longitudinal monitoring of AD with imaging techniques, but all these biomarkers have their limitations regarding specificity, reliability and sensitivity. Future perspectives. Future research should focus on expanding the employment of imaging techniques and identifying novel biomarkers that reflect AD pathology in the earliest stages.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 The Alzheimer’s disease continuum with corresponding pathological changes, biomarkers and clinical diagnosis. Figure adapted from Yoshiyama et al. [21].](https://figures.cochat.ai/paper-figures/5ed93dc48917473ca30ad0e7a8a74987/imaging-techniques-in-alzheimers-disease-a-review-of-applications-in-early-figure-1.jpg)
![Figure 6 Tau spreading pattern in each Braak stage. Spreading pattern of tau throughout the brain from Braak stage I-II to stage III-IV (limbic regions) and stage V-VI (isocortical areas). Figure adapted from Goedert [145] and created with www.BioRender.com (accessed on 11 February 2021).](https://figures.cochat.ai/paper-figures/f800c1b6e6e24d13ba3b3f4e8509a14d/imaging-techniques-in-alzheimers-disease-a-review-of-applications-in-early-figure-6.jpg)


![Figure 4 Accumulation of amyloid-β in AD. Figure adapted from Patterson et al. [89] and created with www.BioRender.com (accessed on 16 November 2020).](https://figures.cochat.ai/paper-figures/49d3fbddca5e428ea039b5bd152e68a0/imaging-techniques-in-alzheimers-disease-a-review-of-applications-in-early-figure-4.jpg)


![Figure 8 Spreading pattern of amyloid-β accumulation throughout the brain. Amyloid-β accumulation starts in frontal areas and spreads to other regions as disease progresses, leading to a plateau in amyloid-β as disease progresses. Figure adapted from Goedert [145] and created with www.BioRender.com (accessed on 11 February 2021).](https://figures.cochat.ai/paper-figures/d4b1f0c188954fbdb7a6946c934ad246/imaging-techniques-in-alzheimers-disease-a-review-of-applications-in-early-figure-8.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, sMRI and (18FDG)-PET indicate neurodegeneration or neuronal injury in the AT(N) framework with limitations in specifically diagnosing AD.”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [370]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“They cannot accurately differentiate AD from other neurodegenerative diseases with similar pathologies, such as frontotemporal degeneration and TDP-43 proteinopathies with medial temporal lobe atrophy.”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [370]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AD diagnosis relies on detecting amyloid and tau pathology via positron emission tomography (PET), magnetic resonance imaging (MRI), and cerebrospinal fluid (CSF) analysis [8,9,10].”
From Theranostic Nanoplatforms for Alzheimer's Disease: A Critical Analysis of Conceptual Contradictions (2026) · cites this paper as [8]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 4×
“, reporting decreased metabolism in the same two medial prefrontal regions [3,157] Altogether, these findings highlight the potential of FDG-PET for the longitudinal monitoring of AD progression.”
BackgroundInfluentialThe Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Huang, D., Swanson, E. A., Lin, C. P., Schuman, J. S., Stinson, W. G., Chang, W., Hee, M. R., Flotte, T., Gregory, K., Puliafito, C. A., et al. (1991) · Science · doi:10.1126/science.1957169 · Cited by 13,788
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Voxel-Based Morphometry—The Methods
Ashburner, J., & Friston, K. J. (2000) · NeuroImage · doi:10.1006/nimg.2000.0582 · Cited by 8,676 · cited 7×
“Currently, two distinct biomarkers are used to assess Aβ pathology: the concentration of Aβ42 in the CSF and 2.3.2.”
MethodInfluentialAlzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484 · cited 2×
“leading to the formation of senile plaques [7,20,82,83].”
BackgroundFunctional connectivity in the resting brain: a network analysis of the default mode hypothesis
Greicius, M. D., Krasnow, B., Reiss, A. L., & Menon, V. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0135058100 · Cited by 6,358
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164 · cited 1×
“All other disease characteristics, such as the formation of NFTs out of hyperphosphorylated tau, and neurodegeneration, are seen a result of this accumulation [12,83,88].”
BackgroundHypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806 · cited 2×
“This statement is further underlined by the hypothetical model of dynamic biomarkers [77,78].”
BackgroundQuerfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496 · cited 1×
“11C-PiB In 2004, a novel 11C radiotracer named Pittsburgh compound-B (PiB) was applied in a study containing mild AD patients and a control group [91].”
MethodJack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Blennow, K., de Leon, M. J., & Zetterberg, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69113-7 · Cited by 3,134
Alzheimer's Disease Neuroimaging Initiative (ADNI)
Petersen, R. C., Aisen, P. S., Beckett, L. A., Donohue, M. C., Gamst, A. C., Harvey, D. J., Jack, C. R., Jagust, W. J., Shaw, L. M., Toga, A. W., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181cb3e25 · Cited by 2,572
Villemagne, V. L., Burnham, S., Bourgeat, P., Brown, B., Ellis, K. A., Salvado, O., Szoeke, C., Macaulay, S. L., Martins, R., Maruff, P., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70044-9 · Cited by 2,279 · cited 1×
“Intensive longitudinal research in a group of two hundred participants revealed that Aβ deposition progresses slowly, likely to be prolonged for more than twenty years [179].”
BackgroundThe clinical use of structural MRI in Alzheimer disease
Frisoni, G. B., Fox, N. C., Jack, C. R., Scheltens, P., & Thompson, P. M. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.215 · Cited by 2,113 · cited 2×
“Whilst structural MRI might not be the most suitable technique for the early diagnosis of AD, many studies have used structural MRI to monitor disease progression, because rates of change in multiple structural measures are closely associated with changes in cognitive abilities [44].”
BackgroundCryo-EM structures of tau filaments from Alzheimer’s disease
Fitzpatrick, A. W. P., Falcon, B., He, S., Murzin, A. G., Murshudov, G., Garringer, H. J., Crowther, R. A., Ghetti, B., Goedert, M., & Scheres, S. H. W. (2017) · Nature · doi:10.1038/nature23002 · Cited by 2,061
Jack, C. R., Albert, M. S., Knopman, D. S., McKhann, G. M., Sperling, R. A., Carrillo, M. C., Thies, B., & Phelps, C. H. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.004 · Cited by 2,042
Preclinical Alzheimer’s Disease: Definition, Natural History, and Diagnostic Criteria
Dubois, B., Hampel, H., Feldman, H. H., Scheltens, P., Aisen, P., Andrieu, S., Bakardjian, H., Benali, H., Bertram, L., Blennow, K., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.002 · Cited by 1,925 · cited 1×
“The above listed events succeed and overlap each other and, therefore, AD is seen as a continuum with pathological changes and clinical symptoms corresponding to the disease stage [13] (Figure 1).”
BackgroundA/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Feldman, H. H., Frisoni, G. B., Hampel, H., Jagust, W. J., Johnson, K. A., Knopman, D. S., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002923 · Cited by 1,864 · cited 1×
“In this so-called “A/T/N” system, “A” refers to biomarkers measuring Aβ deposition, “T” indicates biomarkers sensitive for tau and “N” the value of biomarkers perceptive for neurodegeneration [18].”
BackgroundIron, brain ageing and neurodegenerative disorders
Zecca, L., Youdim, M. B. H., Riederer, P., Connor, J. R., & Crichton, R. R. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1537 · Cited by 1,801 · cited 1×
“Although iron is required for maintaining homeostasis and plays a key role in many biological processes, abnormal accumulation of iron in subcortical and deep gray matter nuclei has been associated with AD [225].”
BackgroundAlzheimer’s disease: pathogenesis, diagnostics, and therapeutics
Tiwari, S., Atluri, V., Kaushik, A., Yndart, A., & Nair, M. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s200490 · Cited by 1,308 · cited 1×
“Therefore, much effort is put into understanding the pathogenesis of AD for the development of therapeutic agents [11].”
BackgroundDickerson, B. C., Bakkour, A., Salat, D. H., Feczko, E., Pacheco, J., Greve, D. N., Grodstein, F., Wright, C. I., Blacker, D., Rosas, H. D., et al. (2009) · Cerebral Cortex · doi:10.1093/cercor/bhn113 · Cited by 1,153 · cited 1×
“Detailed study has demonstrated the effect of AD on cortical thickness and led to the suggestion of a so-called AD “disease signature” in which certain brain regions known to be affected by AD show cortical thinning [38].”
Backgroundvon Braunmühl, T. (2015) · Der Hautarzt · doi:10.1007/s00105-015-3607-z · Cited by 1,033
(1995) · PubMed Central · doi:10.2967/jnumed.120.252510a · Cited by 996
Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging
Rowe, C. C., Ellis, K. A., Rimajova, M., Bourgeat, P., Pike, K. E., Jones, G., Fripp, J., Tochon-Danguy, H., Morandeau, L., O'Keefe, G., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.007 · Cited by 986 · cited 1×
“However, compared to PiB, the fluorinated tracers showed higher levels of non-specific uptake in the white matter due to the more lipophilic nature of both radiotracer and white matter [110,111], resulting in more background noise [112].”
BackgroundGoedert, M. (2015) · Science · doi:10.1126/science.1255555 · Cited by 976 · cited 4×
“Figure adapted fr m Goedert [145] and created with www.”
MethodInfluentialSilverman, D. H. S., Small, G. W., Chang, C. Y., Lu, C. S., de Aburto, M. A. K., Chen, W., Czernin, J., Rapoport, S. I., Pietrini, P., Alexander, G. E., et al. (2001) · JAMA · doi:10.1001/jama.286.17.2120 · Cited by 951
Brain Imaging in Alzheimer Disease
Johnson, K. A., Fox, N. C., Sperling, R. A., & Klunk, W. E. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006213 · Cited by 875 · cited 10×
“It is seen as a robust and reliable biomarker in the in vivo diagnosis of early stages of AD [23,36,43].”
BackgroundMethodInfluentialClark, C. M., Pontecorvo, M. J., Beach, T. G., Bedell, B. J., Coleman, R. E., Doraiswamy, P. M., Fleisher, A. S., Reiman, E. M., Sabbagh, M. N., Sadowsky, C. H., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70142-4 · Cited by 855 · cited 1×
“This pattern was histological confirmed by the comparison of imaging data with immunohistochemical exams post-mortem [97,98].”
ResultLongitudinal assessment of Aβ and cognition in aging and Alzheimer disease
Villemagne, V. L., Pike, K. E., Chételat, G., Ellis, K. A., Mulligan, R. S., Bourgeat, P., Ackermann, U., Jones, G., Szoeke, C., Salvado, O., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22248 · Cited by 833 · cited 1×
“Although a fundamental role of Aβ deposition in the pathogenesis of AD is widely accepted, the relationship between plaque density and disease severity is weak [175,176].”
BackgroundComparison of different MRI brain atrophy rate measures with clinical disease progression in AD
Jack, C. R., Shiung, M. M., Gunter, J. L., O’Brien, P. C., Weigand, S. D., Knopman, D. S., Boeve, B. F., Ivnik, R. J., Smith, G. E., Cha, R. H., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000110315.26026.ef · Cited by 827 · cited 1×
“, the above structural MRI measures were combined and evaluated on their ability to predict disease progression [152].”
BackgroundCreavin, S. T., Wisniewski, S., Noel-Storr, A. H., Trevelyan, C. M., Hampton, T., Rayment, D., Thom, V. M., Nash, K. J. E., Elhamoui, H., Milligan, R., et al. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011145.pub2 · Cited by 820 · cited 1×
“Furthermore, wholebrain atrophy rates and hippocampal volume reduction are not AD-specific measures, and since MMSE is not sensitive enough to diagnose AD [153], atrophy rates and declined cognitive performance might be wrongly attributed to AD.”
BackgroundShoghi-Jadid, K., Small, G. W., Agdeppa, E. D., Kepe, V., Ercoli, L. M., Siddarth, P., Read, S., Satyamurthy, N., Petric, A., Huang, S.-C., et al. (2002) · The American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200201000-00004 · Cited by 770
Maruyama, M., Shimada, H., Suhara, T., Shinotoh, H., Ji, B., Maeda, J., Zhang, M.-R., Trojanowski, J. Q., Lee, V. M.-Y., Ono, M., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.07.037 · Cited by 760
Du, A. T. (2001) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.71.4.441 · Cited by 729 · cited 4×
“Moreover, high variability in methods to assess the entorhinal cortex volume due to anatomic ambiguity in the cortex’s boundaries eliminates the slight superiority of the entorhinal cortex over the hippocampus [29,34,36].”
BackgroundInfluentialWong, D. F., Rosenberg, P. B., Zhou, Y., Kumar, A., Raymont, V., Ravert, H. T., Dannals, R. F., Nandi, A., Brašić, J. R., Ye, W., et al. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.069088 · Cited by 684
Animal models of Alzheimer's disease and frontotemporal dementia
Götz, J., & Ittner, L. M. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2420 · Cited by 676 · cited 1×
“Furthermore, increasing evidence suggests a role for oligomeric Aβ and tau species in the early stages of AD rather than Aβ plaques and NFTs [118,119].”
BackgroundEarly Clinical PET Imaging Results with the Novel PHF-Tau Radioligand [F18]-T808
Chien, D. T., Szardenings, A. K., Bahri, S., Walsh, J. C., Mu, F., Xia, C., Shankle, W. R., Lerner, A. J., Su, M.-Y., Elizarov, A., et al. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-130098 · Cited by 675 · cited 1×
“Moreover, the uptake of flortaucipir corresponds well with the expected spatial pattern of tau pathology in the brain of AD subjects (Figure 3) [140,141].”
BackgroundRowe, C. C., Ackerman, U., Browne, W., Mulligan, R., Pike, K. L., O'Keefe, G., Tochon-Danguy, H., Chan, G., Berlangieri, S. U., Jones, G., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70001-2 · Cited by 671 · cited 1×
“18F-Labelled Radiotracers The short half-life of 11C in PiB led to the development of 18F-labelled radiotracers, and in 2008, the first study reported successful imaging with a fluorinated radiotracer in humans [107].”
BackgroundEarly clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807
Chien, D. T., Bahri, S., Szardenings, A. K., Walsh, J. C., Mu, F., Su, M.-Y., Shankle, W. R., Elizarov, A., & Kolb, H. C. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-122059 · Cited by 651 · cited 1×
“Although 18F−T808 exhibited high tau affinity, rapid uptake and clearance, a disadvantage of this compound was de defluorination followed by bone uptake of 18F [139].”
BackgroundHippocampus and entorhinal cortex in mild cognitive impairment and early AD
Pennanen, C., Kivipelto, M., Tuomainen, S., Hartikainen, P., Hänninen, T., Laakso, M. P., Hallikainen, M., Vanhanen, M., Nissinen, A., Helkala, E.-L., et al. (2004) · Neurobiology of Aging · doi:10.1016/s0197-4580(03)00084-8 · Cited by 643
Post-translational modifications of tau protein: Implications for Alzheimer's disease
Martin, L., Latypova, X., & Terro, F. (2011) · Neurochemistry International · doi:10.1016/j.neuint.2010.12.023 · Cited by 641 · cited 1×
“Several posttranslational processes can modify tau, such as acetylation, glycosylation, methylation and phosphorylation, which affect the ultrastructural conformation of tau [121].”
BackgroundBiomarkers for Alzheimer's disease: academic, industry and regulatory perspectives
Hampel, H., Frank, R., Broich, K., Teipel, S. J., Katz, R. G., Hardy, J., Herholz, K., Bokde, A. L. W., Jessen, F., Hoessler, Y. C., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3115 · Cited by 631 · cited 2×
“In AD, hypometabolism occurs first in the temporoparietal areas of the brain, including the precuneus and posterior cingulate cortex [1,61] (Figure 2).”
BackgroundStrategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers
Frisoni, G. B., Boccardi, M., Barkhof, F., Blennow, K., Cappa, S., Chiotis, K., Démonet, J.-F., Garibotto, V., Giannakopoulos, P., Gietl, A., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30159-x · Cited by 626 · cited 2×
“and clinical validation of the tracers is required [146].”
BackgroundAntemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia
Jack, C. R., Dickson, D. W., Parisi, J. E., Xu, Y. C., Cha, R. H., O’Brien, P. C., Edland, S. D., Smith, G. E., Boeve, B. F., Tangalos, E. G., et al. (2002) · Neurology · doi:10.1212/wnl.58.5.750 · Cited by 610 · cited 3×
“scans of the hippocampus (Figure 3) [25].”
BackgroundMethodMapping hippocampal and ventricular change in Alzheimer disease
Thompson, P. M., Hayashi, K. M., de Zubicaray, G. I., Janke, A. L., Rose, S. E., Semple, J., Hong, M. S., Herman, D. H., Gravano, D., Doddrell, D. M., et al. (2004) · NeuroImage · doi:10.1016/j.neuroimage.2004.03.040 · Cited by 607
Imaging the evolution and pathophysiology of Alzheimer disease
Jagust, W. (2018) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0067-3 · Cited by 604 · cited 1×
“Although a fundamental role of Aβ deposition in the pathogenesis of AD is widely accepted, the relationship between plaque density and disease severity is weak [175,176].”
BackgroundSiebner, H., Riemenschneider, M., Willoch, F., Minoshima, S., Schwaiger, M., Kurz, A., Drzezga, A., & Lautenschlager, N. (2003) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-003-1194-1 · Cited by 603 · cited 1×
“MCI subjects underwent two FDG-PET scans with an interval of one year to identify typical patterns of cerebral metabolism [155].”
BackgroundGordon, B. A., Blazey, T. M., Su, Y., Hari-Raj, A., Dincer, A., Flores, S., Christensen, J., McDade, E., Wang, G., Xiong, C., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30028-0 · Cited by 602 · cited 2×
“Altogether, Aβ-PET collected the first in vivo evidence of earliest protein deposition [114].”
BackgroundResultHansson, O., Lehmann, S., Otto, M., Zetterberg, H., & Lewczuk, P. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0485-0 · Cited by 585 · cited 1×
“Currently, two distinct biomarkers are used to assess Aβ pathology: the concentration of Aβ42 in the CSF and amyloid-PET [1,77,90].”
BackgroundImaging synaptic density in the living human brain
Finnema, S. J., Nabulsi, N. B., Eid, T., Detyniecki, K., Lin, S.-F., Chen, M.-K., Dhaher, R., Matuskey, D., Baum, E., Holden, D., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf6667 · Cited by 575 · cited 1×
“18F-UCBJ is a PET radiotracer considered to be sensitive for synaptic loss, because altered uptake of 18F-UCB-J in the gray matter was correlated to altered expression of SV2A and lower synaptic density [219,220].”
BackgroundLongstreth, W. T. (1998) · Archives of Neurology · doi:10.1001/archneur.55.9.1217 · Cited by 573 · cited 1×
“Since approximately 30% of elderly people suffer from a silent infarct, lacking any clinical manifestations [172], alterations in cerebral glucose metabolism are not surprising in this aged population [173].”
BackgroundMRI measures of entorhinal cortex vs hippocampus in preclinical AD
Killiany, R. J., Hyman, B. T., Gomez-Isla, T., Moss, M. B., Kikinis, R., Jolesz, F., Tanzi, R., Jones, K., & Albert, M. S. (2002) · Neurology · doi:10.1212/wnl.58.8.1188 · Cited by 567 · cited 2×
“of entorhinal cortex volumetry being slightly higher [32], several cross-sectional studies suggested that entorhinal cortex measurements are unlikely to offer additional benefits over hippocampal volumetry in AD patients when compared to healthy controls [33–35].”
BackgroundResultOssenkoppele, R., Pijnenburg, Y. A. L., Perry, D. C., Cohn-Sheehy, B. I., Scheltens, N. M. E., Vogel, J. W., Kramer, J. H., van der Vlies, A. E., Joie, R. L., Rosen, H. J., et al. (2015) · Brain · doi:10.1093/brain/awv191 · Cited by 548 · cited 1×
“In typical AD, key regions of atrophy are the hippocampus and ERC, whilst in atypical AD, such as the previously mentioned LvPPA and PCA, but also the dysexecutive/behavioral variant [154], these regions undergo slower rates of change [58,59].”
BackgroundHippocampal formation glucose metabolism and volume losses in MCI and AD
De Santi, S., de Leon, M. J., Rusinek, H., Convit, A., Tarshish, C. Y., Roche, A., Tsui, W. H., Kandil, E., Boppana, M., Daisley, K., et al. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00230-5 · Cited by 548 · cited 1×
“Moreover, compared to structural MRI of the hippocampus and entorhinal cortex, FDG-PET is diagnostically superior to volumetry measures [76].”
BackgroundAlzheimer's disease: Focal cortical changes shown by positron emission tomography
Foster, N. L., Chase, T. N., Fedio, P., Patronas, N. J., Brooks, R. A., & Chiro, G. D. (1983) · Neurology · doi:10.1212/wnl.33.8.961 · Cited by 540
Core candidate neurochemical and imaging biomarkers of Alzheimer's disease
Hampel, H., Bürger, K., Teipel, S. J., Bokde, A. L. W., Zetterberg, H., & Blennow, K. (2008) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2007.08.006 · Cited by 532
Clinical core of the Alzheimer's disease neuroimaging initiative: Progress and plans
Aisen, P. S., Petersen, R. C., Donohue, M. C., Gamst, A., Raman, R., Thomas, R. G., Walter, S., Trojanowski, J. Q., Shaw, L. M., Beckett, L. A., et al. (2010) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2010.03.006 · Cited by 517 · cited 1×
“Classification into early MCI or late MCI is solely based on the outcome of the WMS-R Logical Memory II test, and the ADNI refers to early MCI subjects as patients that meet all the criteria for aMCI, but are in an earlier, and, therefore, less severe, point on the clinical spectrum [158,159].”
MethodEvidence for more widespread cerebral pathology in early HD: An MRI-based morphometric analysis
Rosas, H. D., Koroshetz, W. J., Chen, Y. I., Skeuse, C., Vangel, M., Cudkowicz, M. E., Caplan, K., Marek, K., Seidman, L. J., Makris, N., et al. (2003) · Neurology · doi:10.1212/01.wnl.0000065888.88988.6e · Cited by 505
Tau imaging: early progress and future directions
Villemagne, V. L., Fodero-Tavoletti, M. T., Masters, C. L., & Rowe, C. C. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70252-2 · Cited by 501 · cited 12×
“Second, the i tracellular location of NTFs poses a se nd barri r for the radiotracer to overcome [4,117,127].”
BackgroundInfluentialThe importance of tau phosphorylation for neurodegenerative diseases
Noble, W., Hanger, D. P., Miller, C. C. J., & Lovestone, S. (2013) · Frontiers in Neurology · doi:10.3389/fneur.2013.00083 · Cited by 475 · cited 1×
“Although normal phosphorylation of tau is required for its role in cytoskeletal plasticity during early development [122], hyperphosphorylation combined with decreased dephosphorylation leads to soluble hyperphosphorylated tau [123] that rapidly aggregates into so-called tauopathies [124].”
BackgroundFriedland, R. P., Budinger, T. F., Ganz, E., Yano, Y., Mathis, C. A., Koss, B., Ober, B. A., Huesman, R. H., & Derenzo, S. E. (1983) · Journal of Computer Assisted Tomography · doi:10.1097/00004728-198308000-00003 · Cited by 468
Landau, S. M., Breault, C., Joshi, A. D., Pontecorvo, M., Mathis, C. A., Jagust, W. J., & Mintun, M. A. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.109009 · Cited by 462 · cited 2×
“First, the short half-life (twenty minutes) of the 11C isotope requires a nearby cyclotron for clinical usage [86,103].”
Bobinski, M., de Leon, M. J., Wegiel, J., DeSanti, S., Convit, A., Saint Louis, L. A., Rusinek, H., & Wisniewski✠, H. M. (1999) · Neuroscience · doi:10.1016/s0306-4522(99)00476-5 · Cited by 455 · cited 2×
“numbers, suggesting the anatomic validity of volumetric MRI measurements [28].”
BackgroundMethodLongitudinal tau PET in ageing and Alzheimer’s disease
Jack, C. R., Wiste, H. J., Schwarz, C. G., Lowe, V. J., Senjem, M. L., Vemuri, P., Weigand, S. D., Therneau, T. M., Knopman, D. S., Gunter, J. L., et al. (2018) · Brain · doi:10.1093/brain/awy059 · Cited by 452 · cited 2×
“cognitive impairment, but abnormal Aβ, and cognitively impaired subjects with abnormal Aβ and an amnestic phenotype [187].”
BackgroundFocal Decline of Cortical Thickness in Alzheimer's Disease Identified by Computational Neuroanatomy
Lerch, J. P., Pruessner, J. C., Zijdenbos, A., Hampel, H., Teipel, S. J., & Evans, A. C. (2005) · Cerebral Cortex · doi:10.1093/cercor/bhh200 · Cited by 431 · cited 2×
“areas, such as the temporal, orbitofrontal and parietal regions [37].”
BackgroundMethodA new amyloid β variant favoring oligomerization in Alzheimer's‐type dementia
Tomiyama, T., Nagata, T., Shimada, H., Teraoka, R., Fukushima, A., Kanemitsu, H., Takuma, H., Kuwano, R., Imagawa, M., Ataka, S., et al. (2008) · Annals of Neurology · doi:10.1002/ana.21321 · Cited by 421 · cited 1×
“Second, as previously mentioned, PiB has the tendency to only bind to the fibrillar form of Aβ and has low affinity for soluble oligomeric Aβ [104], while it is believed that in some genetic forms of AD, oligomeric Aβ plays a significant role in the disease manifestations [105,106].”
BackgroundMR-based in vivo hippocampal volumetrics: 2. Findings in neuropsychiatric disorders
Geuze, E., Vermetten, E., & Bremner, J. D. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001579 · Cited by 412 · cited 1×
“reviewed more than 420 records reporting the assessment of hippocampal volume with MRI [45].”
Background11 C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration
Rabinovici, G. D., Furst, A. J., O'Neil, J. P., Racine, C. A., Mormino, E. C., Baker, S. L., Chetty, S., Patel, P., Pagliaro, T. A., Klunk, W. E., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000259035.98480.ed · Cited by 410 · cited 5×
“Rabinovici et al. demonstrated that amyloid-PET imaging with PiB was able to distinguish AD subjects from patients with other forms of dementia, such as frontotemporal dementia (FTD) [92].”
BackgroundInfluentialBrain β-amyloid load approaches a plateau
Jack, C. R., Wiste, H. J., Lesnick, T. G., Weigand, S. D., Knopman, D. S., Vemuri, P., Pankratz, V. S., Senjem, M. L., Gunter, J. L., Mielke, M. M., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e3182840bbe · Cited by 406 · cited 3×
“As mentioned above, it is hypothesized that Aβ burden reaches a plateau as AD progresses [180,184], making longitudinal tracking of Aβ accumulation not the most promising biomarker for disease progression.”
BackgroundFDG PET imaging in patients with pathologically verified dementia.
Hoffman, J. M., Welsh-Bohmer, K. A., Hanson, M., Crain, B. J., Hulette, C. M., Earl, N., & Coleman, R. E. (2000) · PubMed · Cited by 399
The Fluorodeoxyglucose 18F Scan in Alzheimer's Disease and Multi-infarct Dementia
Benson, D. F., Kuhl, D. E., Hawkins, R. A., Phelps, M. E., Cummings, J. L., & Tsai, S. Y. (1983) · Archives of Neurology · doi:10.1001/archneur.1983.04050110029003 · Cited by 392 · cited 1×
“in 1983 in which both AD patients and patients with multi-infarct dementia were studied [63].”
BackgroundAlzheimer-signature MRI biomarker predicts AD dementia in cognitively normal adults
Dickerson, B. C., Stoub, T. R., Shah, R. C., Sperling, R. A., Killiany, R. J., Albert, M. S., Hyman, B. T., Blacker, D., & deToledo-Morrell, L. (2011) · Neurology · doi:10.1212/wnl.0b013e3182166e96 · Cited by 383 · cited 1×
“Assessment of the cortical thickness is believed to be a useful biomarker in the early diagnosis of AD, since subtle changes in areas known to be affected by AD can be detected [39].”
BackgroundBrain PET in the Diagnosis of Alzheimer’s Disease
Marcus, C., Mena, E., & Subramaniam, R. M. (2014) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000000547 · Cited by 382 · cited 2×
“responding cerebral metabolism patterns [62].”
BackgroundMagnetic resonance imaging in Alzheimer’s disease and mild cognitive impairment
Initiative, F. T. A. D. N., Chandra, A., Dervenoulas, G., & Politis, M. (2019) · Journal of Neurology · doi:10.1007/s00415-018-9016-3 · Cited by 382 · cited 2×
“This technique measures the displacement of water molecules in three dimensions to determine the integrity of the biological tissue [202,203].”
BackgroundMethodLandau, S. M., Fero, A., Baker, S. L., Koeppe, R., Mintun, M., Chen, K., Reiman, E. M., & Jagust, W. J. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.148981 · Cited by 364 · cited 2×
“It has, therefore, been suggested to combine multiple reference regions into one more alike to the longitudinal changes to minimize potential variations [183].”
BackgroundHippocampal Volume in Patients With Alcohol Dependence
Agartz, I., Momenan, R., Rawlings, R. R., Kerich, M. J., & Hommer, D. W. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.4.356 · Cited by 361 · cited 2×
“Additionally, volume reduction has also been observed after cardiac arrest [49], chronic alcohol abuse [50] and survivors of low birth weight [51].”
BackgroundHua, X., Leow, A. D., Parikshak, N., Lee, S., Chiang, M.-C., Toga, A. W., Jack, C. R., Weiner, M. W., & Thompson, P. M. (2008) · NeuroImage · doi:10.1016/j.neuroimage.2008.07.013 · Cited by 360 · cited 1×
“With tensor-based morphometry (TBM), regional differences in gradients of the deformation fields that line up the images into the template brain are measured [198].”
Usefulness of MRI measures of entorhinal cortex versus hippocampus in AD
de Leon, M., Bobinski, M., Convit, A., Wolf, O., & Insausti, R. (2001) · Neurology · doi:10.1212/wnl.56.6.820 · Cited by 348
Parkinson's disease is associated with hippocampal atrophy
Camicioli, R., Moore, M. M., Kinney, A., Corbridge, E., Glassberg, K., & Kaye, J. A. (2003) · Movement Disorders · doi:10.1002/mds.10444 · Cited by 343 · cited 2×
“In addition to AD, other neurodegenerative diseases are characterized with diminished hippocampal volume as well such as Parkinson’s disease [46], epilepsy [47] and Huntington’s disease [48].”
BackgroundMCI conversion to dementia and the APOE genotype: A prediction study with FDG-PET
Mosconi, L., Perani, D., Sorbi, S., Herholz, K., Nacmias, B., Holthoff, V., Salmon, E., Baron, J.-C., De Cristofaro, M. T. R., Padovani, A., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000147469.18313.3b · Cited by 343
[18F]FDG PET signal is driven by astroglial glutamate transport
Zimmer, E. R., Parent, M. J., Souza, D. G., Leuzy, A., Lecrux, C., Kim, H.-I., Gauthier, S., Pellerin, L., Hamel, E., & Rosa-Neto, P. (2017) · Nature Neuroscience · doi:10.1038/nn.4492 · Cited by 343 · cited 3×
“lism can be ascribed to decreased astrocyte function [80].”
BackgroundChupin, M., Gérardin, E., Cuingnet, R., Boutet, C., Lemieux, L., Lehéricy, S., Benali, H., Garnero, L., & Colliot, O. (2009) · Hippocampus · doi:10.1002/hipo.20626 · Cited by 339
Correlation between rates of brain atrophy and cognitive decline in AD
Fox, N. C., Scahill, R. I., Crum, W. R., & Rossor, M. N. (1999) · Neurology · doi:10.1212/wnl.52.8.1687 · Cited by 338 · cited 1×
“in 1999, whole-brain atrophy was linked to increased disease severity [147].”
BackgroundUsefulness of MRI measures of entorhinal cortex versus hippocampus in AD
Xu, Y., Jack, C. R., O’Brien, P. C., Kokmen, E., Smith, G. E., Ivnik, R. J., Boeve, B. F., Tangalos, R. G., & Petersen, R. C. (2000) · Neurology · doi:10.1212/wnl.54.9.1760 · Cited by 336
18F-THK5351: A Novel PET Radiotracer for Imaging Neurofibrillary Pathology in Alzheimer Disease
Harada, R., Okamura, N., Furumoto, S., Furukawa, K., Ishiki, A., Tomita, N., Tago, T., Hiraoka, K., Watanuki, S., Shidahara, M., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.164848 · Cited by 330 · cited 1×
“This new compound exhibited rapid clearance from the white matter [137].”
BackgroundMosconi, L. (2013) · Clinical and Translational Imaging · doi:10.1007/s40336-013-0026-y · Cited by 328 · cited 2×
“In this so-called topographic pattern that characterizes AD, the earliest changes are found in the medial temporal lobe structures, the entorhinal and perirhinal cortex and the hippocampus [16] (Figure 2).”
BackgroundAnchisi, D., Borroni, B., Franceschi, M., Kerrouche, N., Kalbe, E., Beuthien-Beumann, B., Cappa, S., Lenz, O., Ludecke, S., Marcone, A., et al. (2005) · Archives of Neurology · doi:10.1001/archneur.62.11.1728 · Cited by 323
Senile plaque neurites in Alzheimer disease accumulate amyloid precursor protein.
Cras, P., Kawai, M., Lowery, D., Gonzalez-DeWhitt, P., Greenberg, B., & Perry, G. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.17.7552 · Cited by 319 · cited 1×
“The senile plaques contain primarily neurotoxic amyloid-β (Aβ) [5], whereas NFTs consist of abnormal hyperphosphorylated tau aggregates [6,7].”
BackgroundPrediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET.
Drzezga, A. E., Grimmer, T., Riemenschneider, M., Lautenschlager, N. T., Siebner, H. R., Alexopoulus, P., Minoshima, S., Schwaiger, M., & Kurz, A. (2005) · UWA Profiles and Research Repository (UWA) · Cited by 319
Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease
Ossenkoppele, R., Smith, R., Ohlsson, T., Strandberg, O., Mattsson, N., Insel, P. S., Palmqvist, S., & Hansson, O. (2019) · Neurology · doi:10.1212/wnl.0000000000006875 · Cited by 317
Molecular characterization of microtubule-associated proteins tau and map2
Goedert, M., Crowther, R. A., & Garner, C. C. (1991) · Trends in Neurosciences · doi:10.1016/0166-2236(91)90105-4 · Cited by 315 · cited 1×
“Tau is a microtubuleassociated protein with six isoforms and is abundantly expressed in the CNS where it stabilizes the microtubules of axons (Figure 5) [120].”
BackgroundWhat does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia?
Jagust, W., Reed, B., Mungas, D., Ellis, W., & DeCarli, C. (2007) · Neurology · doi:10.1212/01.wnl.0000269790.05105.16 · Cited by 298 · cited 1×
“The findings were underlined with other research studies with sensitivity ranging from 84% to 93% and specificity between 63% and 74% [70,71].”
BackgroundOkamura, N., Furumoto, S., Harada, R., Tago, T., Yoshikawa, T., Fodero-Tavoletti, M., Mulligan, R. S., Villemagne, V. L., Akatsu, H., Yamamoto, T., et al. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.117341 · Cited by 290 · cited 1×
“These two compounds were developed to enhance the binding affinity to PHF-tau [7] and demonstrated binding affinity and selectivity to PHF-tau over amyloid-β in AD [134].”
BackgroundBohnen, N. I., Djang, D. S. W., Herholz, K., Anzai, Y., & Minoshima, S. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.096578 · Cited by 286 · cited 1×
“Although in this study, longitudinal clinical follow-up was included, this was primarily conducted as a diagnostic reference standard [74].”
MethodReview and Meta-Analysis of Biomarkers and Diagnostic Imaging in Alzheimer's Disease
Bloudek, L. M., Spackman, D. E., Blankenburg, M., & Sullivan, S. D. (2011) · Journal of Alzheimer’s Disease · doi:10.3233/jad-2011-110458 · Cited by 282
Tau PET imaging: present and future directions
Saint-Aubert, L., Lemoine, L., Chiotis, K., Leuzy, A., Rodriguez-Vieitez, E., & Nordberg, A. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0162-3 · Cited by 282 · cited 8×
“Based on their structures, the currently available tau tracers can be divided into four groups: the nonselective tracer 18F-FDDNP, quinoline derivatives, pyrido−indole derivatives and PBB3 [123,124].”
BackgroundInfluentialColliot, O., Chételat, G., Chupin, M., Desgranges, B., Magnin, B., Benali, H., Dubois, B., Garnero, L., Eustache, F., & Lehéricy, S. (2008) · Radiology · doi:10.1148/radiol.2481070876 · Cited by 280 · cited 2×
“hippocampal atrophy can be measured with either manual or automated segmentation [27].”
MethodPre-Clinical Detection of Alzheimer's Disease Using FDG-PET, with or without Amyloid Imaging
Mosconi, L., Berti, V., Glodzik, L., Pupi, A., De Santi, S., & de Leon, M. J. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-091504 · Cited by 277 · cited 1×
“Over the years, FDG-PET emerged to be a relevant and highly specific biomarker for the early diagnosis of AD and other types of major neurodegenerative diseases [43,75].”
BackgroundDiagnosis and treatment of dementia: 1. Risk assessment and primary prevention of Alzheimer disease
Patterson, C., Feightner, J. W., Garcia, A., Hsiung, G.-Y. R., MacKnight, C., & Sadovnick, A. D. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.070796 · Cited by 268
Longitudinal tau accumulation and atrophy in aging and alzheimer disease
Harrison, T. M., La Joie, R., Maass, A., Baker, S. L., Swinnerton, K., Fenton, L., Mellinger, T. J., Edwards, L., Pham, J., Miller, B. L., et al. (2019) · Annals of Neurology · doi:10.1002/ana.25406 · Cited by 268 · cited 1×
“in which healthy adults with normal Aβ showed observable tau accumulation associated with brain atrophy [188].”
BackgroundNon-invasive assessment of Alzheimer’s disease neurofibrillary pathology using 18F-THK5105 PET
Okamura, N., Furumoto, S., Fodero-Tavoletti, M. T., Mulligan, R. S., Harada, R., Yates, P., Pejoska, S., Kudo, Y., Masters, C. L., Yanai, K., et al. (2014) · Brain · doi:10.1093/brain/awu064 · Cited by 264 · cited 1×
“Moreover, clinical PET studies revealed that these radiotracers were able to differentiate brains of AD subjects from brains of healthy controls [135,136].”
BackgroundRowe, C. C., & Villemagne, V. L. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.076315 · Cited by 261 · cited 1×
“Due to this extra noise, the typical white matter pattern caused by cortical amyloid plaque is lost [113].”
BackgroundPaudel, Y. N., Angelopoulou, E., Piperi, C., Othman, I., Aamir, K., & Shaikh, M. F. (2020) · Cells · doi:10.3390/cells9020383 · Cited by 257 · cited 1×
“Moreover, RAGE levels are significantly higher in AD subjects than in cognitively healthy controls [222].”
BackgroundMorris, E., Chalkidou, A., Hammers, A., Peacock, J., Summers, J., & Keevil, S. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3228-x · Cited by 248 · cited 1×
“differences between the diagnostic accuracy of the radiotracers [109].”
BackgroundAtrophy patterns in early clinical stages across distinct phenotypes of Alzheimer's disease
Ossenkoppele, R., Cohn‐Sheehy, B. I., La Joie, R., Vogel, J. W., Möller, C., Lehmann, M., van Berckel, B. N. M., Seeley, W. W., Pijnenburg, Y. A., Gorno‐Tempini, M. L., et al. (2015) · Human Brain Mapping · doi:10.1002/hbm.22927 · Cited by 243 · cited 2×
“However, in atypical variants of AD, the exact spreading pattern may be distinct from typical AD, and these differences in spreading patterns characterize atypical variants in early stages [125].”
BackgroundBiomarkers for the Early Detection and Progression of Alzheimer's Disease
Counts, S. E., Ikonomovic, M. D., Mercado, N., Vega, I. E., & Mufson, E. J. (2017) · Neurotherapeutics · doi:10.1007/s13311-016-0481-z · Cited by 224 · cited 3×
“leading to the formation of senile plaques [7,20,82,83].”
BackgroundMRI and CSF studies in the early diagnosis of Alzheimer's disease
De Leon, M. J., DeSanti, S., Zinkowski, R., Mehta, P. D., Pratico, D., Segal, S., Clark, C., Kerkman, D., DeBernardis, J., Li, J., et al. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01381.x · Cited by 218 · cited 2×
“Since neuronal damage in the hippocampus is manifested as decreased hippocampal volume [26], a widely accepted method for assessing AD pathology is volumetric MRI”
MethodIn vivo amyloid imaging with PET in frontotemporal dementia
Engler, H., Santillo, A. F., Wang, S. X., Lindau, M., Savitcheva, I., Nordberg, A., Lannfelt, L., Långström, B., & Kilander, L. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-007-0523-1 · Cited by 214 · cited 1×
“In total, 8/10 FTD patients showed a significantly lower retention time compared to AD subjects, indicating that PiB might be a tool in differentiating FTD from AD [93].”
ResultOkamura, N., Suemoto, T., Furumoto, S., Suzuki, M., Shimadzu, H., Akatsu, H., Yamamoto, T., Fujiwara, H., Nemoto, M., Maruyama, M., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.1738-05.2005 · Cited by 212 · cited 2×
“synthesized three new compounds, BF-126, BF-158 and BF-170, as possible probes for in vivo tau-PET imaging in the brain [133].”
BackgroundMorris, G. P., Clark, I. A., & Vissel, B. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1918-8 · Cited by 212 · cited 1×
“However, this belief is still subject to debate [84,85].”
BackgroundSchmitter, D., Roche, A., Maréchal, B., Ribes, D., Abdulkadir, A., Bach-Cuadra, M., Daducci, A., Granziera, C., Klöppel, S., Maeder, P., et al. (2015) · NeuroImage: Clinical · doi:10.1016/j.nicl.2014.11.001 · Cited by 204 · cited 1×
“In AD, VBM is used to quantify atrophy and to automatically distinguish AD patients from MCI subjects and healthy controls [195].”
MethodCerebral perfusion SPET correlated with Braak pathological stage in Alzheimer's disease
Bradley, K. M. (2002) · Brain · doi:10.1093/brain/awf185 · Cited by 203 · cited 1×
“, reporting decreased metabolism in the same two medial prefrontal regions [3,157] Altogether, these findings highlight the potential of FDG-PET for the longitudinal monitoring of AD progression.”
BackgroundFDG PET and Differential Diagnosis of Dementia
Herholz, K. (1995) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199505000-00004 · Cited by 200 · cited 1×
“In the 1990s, automated methods to standardize the evaluation of PET scans increased, leading to more consistency in the evaluation of FDG-PET images obtained in different research centers or with different equipment [67,68].”
MethodRelevance of Magnetic Resonance Imaging for Early Detection and Diagnosis of Alzheimer Disease
Teipel, S. J., Grothe, M., Lista, S., Toschi, N., Garaci, F. G., & Hampel, H. (2013) · Medical Clinics of North America · doi:10.1016/j.mcna.2012.12.013 · Cited by 192 · cited 6×
“tocols for assessing the measurements [33].”
BackgroundMethodInfluentialComparison of 18F-FDG and PiB PET in Cognitive Impairment
Lowe, V. J., Kemp, B. J., Jack, C. R., Senjem, M., Weigand, S., Shiung, M., Smith, G., Knopman, D., Boeve, B., Mullan, B., et al. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.058529 · Cited by 192 · cited 1×
“, PiB-PET was able to significantly differentiated healthy controls from non-amnestic MCI and amnestic MIC, and AD [94].”
BackgroundPathological correlations of [F‐18]‐AV‐1451 imaging in non‐alzheimer tauopathies
Marquié, M., Normandin, M. D., Meltzer, A. C., Siao Tick Chong, M., Andrea, N. V., Antón‐Fernández, A., Klunk, W. E., Mathis, C. A., Ikonomovic, M. D., Debnath, M., et al. (2017) · Annals of Neurology · doi:10.1002/ana.24844 · Cited by 190 · cited 1×
“Furthermore, it is believed that flortaucipir binds with high affinity to all three isoforms of tau when in the classical PHF form [142], which is likely due to its high affinity for more than one binding site of the tau fibril [129].”
BackgroundAmyloid PET imaging in patients with mild cognitive impairment: A 2-year follow-up study
Koivunen, J., Scheinin, N., Virta, J. R., Aalto, S., Vahlberg, T., Någren, K., Helin, S., Parkkola, R., Viitanen, M., & Rinne, J. O. (2011) · Neurology · doi:10.1212/wnl.0b013e318212015e · Cited by 188 · cited 1×
“, changes in Aβ burden were evaluated over a period of two years [177].”
BackgroundThe potential of functional MRI as a biomarker in early Alzheimer's disease
Sperling, R. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.09.009 · Cited by 187 · cited 1×
“Functional MRI (fMRI) is an imaging technique that gives insight into the functional integrity of brain networks that support several cognitive domains in a non-invasive manner [23,208].”
BackgroundThe development and validation of tau PET tracers: current status and future directions
Okamura, N., Harada, R., Ishiki, A., Kikuchi, A., Nakamura, T., & Kudo, Y. (2018) · Clinical and Translational Imaging · doi:10.1007/s40336-018-0290-y · Cited by 181 · cited 7×
“The senile plaques contain primarily neurotoxic amyloid-β (Aβ) [5], whereas NFTs consist of abnormal hyperphosphorylated tau aggregates [6,7].”
BackgroundInfluentialOptical Coherence Tomography in Alzheimer’s Disease and Other Neurodegenerative Diseases
Doustar, J., Torbati, T., Black, K. L., Koronyo, Y., & Koronyo-Hamaoui, M. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00701 · Cited by 176
Lynch, C. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.038255 · Cited by 175 · cited 1×
“AD is the most common cause of dementia and is predicted to affect more than 152 million people in 2050 [2].”
BackgroundWhole-Brain Atrophy Rate and Cognitive Decline: Longitudinal MR Study of Memory Clinic Patients
Sluimer, J. D., van der Flier, W. M., Karas, G. B., Fox, N. C., Scheltens, P., Barkhof, F., & Vrenken, H. (2008) · Radiology · doi:10.1148/radiol.2482070938 · Cited by 174 · cited 2×
“Two other studies also investigated the correlation between whole brain atrophy rates and cognitive performance and underlined the finding that whole-brain atrophy is strongly associated with cognitive decline, making cerebral atrophy an interestingly and clinically relevant biomarker for tracking AD progression [148,…”
BackgroundMRI morphometry in Alzheimer’s disease
Matsuda, H. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.01.003 · Cited by 173
FDG-PET imaging in mild traumatic brain injury: a critical review
Byrnes, K. R., Wilson, C. M., Brabazon, F., von Leden, R., Jurgens, J. S., Oakes, T. R., & Selwyn, R. G. (2014) · Frontiers in Neuroenergetics · doi:10.3389/fnene.2013.00013 · Cited by 171
SPECT and PET imaging in Alzheimer’s disease
Valotassiou, V., Malamitsi, J., Papatriantafyllou, J., Dardiotis, E., Tsougos, I., Psimadas, D., Alexiou, S., Hadjigeorgiou, G., & Georgoulias, P. (2018) · Annals of Nuclear Medicine · doi:10.1007/s12149-018-1292-6 · Cited by 169
Brain atrophy associated with baseline and longitudinal measures of cognition
Cardenas, V. A., Chao, L. L., Studholme, C., Yaffe, K., Miller, B. L., Madison, C., Buckley, S. T., Mungas, D., Schuff, N., & Weiner, M. W. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.04.011 · Cited by 163 · cited 3×
“focused on identifying spatial patterns of brain atrophy associated with cognitive performance and possible future cognitive decline [150].”
BackgroundInfluentialGong, N.-J., Dibb, R., Bulk, M., van der Weerd, L., & Liu, C. (2019) · NeuroImage · doi:10.1016/j.neuroimage.2019.02.019 · Cited by 162 · cited 2×
“Multiple studies have used quantitative susceptibility mapping (QSM) to quantify the local magnetic susceptibility derived from MRI images caused by deposits containing both Aβ and iron [224,226,227].”
BackgroundBiological markers of amyloid β-related mechanisms in Alzheimer's disease
Hampel, H., Shen, Y., Walsh, D. M., Aisen, P., Shaw, L. M., Zetterberg, H., Trojanowski, J. Q., & Blennow, K. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2009.09.024 · Cited by 160 · cited 1×
“Moreover, a good biomarker has high sensitivity and predictive qualities for the specific pathological event [15].”
BackgroundLongitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET
Ossenkoppele, R., Tolboom, N., Foster-Dingley, J. C., Adriaanse, S. F., Boellaard, R., Yaqub, M., Windhorst, A. D., Barkhof, F., Lammertsma, A. A., Scheltens, P., et al. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2102-3 · Cited by 160 · cited 1×
“Another study consolidated the earlier findings by stating that a positive PiB scan is a strong indication for progression of MCI into AD [178].”
ResultChen, K., Roontiva, A., Thiyyagura, P., Lee, W., Liu, X., Ayutyanont, N., Protas, H., Luo, J. L., Bauer, R., Reschke, C., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.149732 · Cited by 157 · cited 1×
“Since these types of plaques are only scarcely pr sented in the cerebellum, this region is often used as a reference region for many Aβ-PET studies [181].”
BackgroundQuantitative magnetic resonance imaging of the brain in survivors of very low birth weight
Abernethy, L. J. (2002) · Archives of Disease in Childhood · doi:10.1136/adc.87.4.279 · Cited by 157
FDG-PET as an independent biomarker for Alzheimer’s biological diagnosis: A longitudinal study
Initiative, O. B. O. A. D. N., Ou, Y.-N., Xu, W., Li, J.-Q., Guo, Y., Cui, M., Chen, K.-L., Huang, Y.-Y., Dong, Q., Tan, L., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0512-1 · Cited by 155 · cited 1×
“because, as mentioned before, FDG uptake is likely to reflect the glucose consumption by astrocytes instead of neurons [80,174].”
BackgroundHashimoto, H., Kawamura, K., Igarashi, N., Takei, M., Fujishiro, T., Aihara, Y., Shiomi, S., Muto, M., Ito, T., Furutsuka, K., et al. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.139550 · Cited by 151 · cited 4×
“The drawbacks of PBB3 are the usage of short half-life 11C in the radiotracer and the ability of its major metabolite to cross the BBB [143,144].”
BackgroundInfluentialOptical coherence tomography angiography in preclinical Alzheimer’s disease
van de Kreeke, J. A., Nguyen, H., Konijnenberg, E., Tomassen, J., den Braber, A., ten Kate, M., Yaqub, M. M., van Berckel, B. N. M., Lammertsma, A. A., Boomsma, D. I., et al. (2019) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2019-314127 · Cited by 151
Longitudinal brain metabolic changes from amnestic mild cognitive impairment to Alzheimer's disease
Fouquet, M., Desgranges, B., Landeau, B., Duchesnay, E., Mézenge, F., de la Sayette, V., Viader, F., Baron, J.-C., Eustache, F., & Chételat, G. (2009) · Brain · doi:10.1093/brain/awp132 · Cited by 147
Caminiti, S. P., Ballarini, T., Sala, A., Cerami, C., Presotto, L., Santangelo, R., Fallanca, F., Vanoli, E. G., Gianolli, L., Iannaccone, S., et al. (2018) · NeuroImage: Clinical · doi:10.1016/j.nicl.2018.01.019 · Cited by 147 · cited 1×
“Additionally, this heterogeneity turned out to be of value in predicting progression to different forms of dementia in the prodromal MCI phase [170].”
BackgroundLiu, X., Chen, K., Wu, T., Weidman, D., Lure, F., & Li, J. (2018) · Translational Research · doi:10.1016/j.trsl.2018.01.001 · Cited by 141 · cited 3×
“Nowadays, imaging modalities focus on either identifying amyloid deposition or identifying neurodegeneration [24].”
BackgroundInfluentialAlzheimer Disease: Operating Characteristics of PET— A Meta-Analysis
Patwardhan, M. B., McCrory, D. C., Matchar, D. B., Samsa, G. P., & Rutschmann, O. T. (2004) · Radiology · doi:10.1148/radiol.2311021620 · Cited by 137
[18F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer’s disease
Harada, R., Okamura, N., Furumoto, S., Furukawa, K., Ishiki, A., Tomita, N., Hiraoka, K., Watanuki, S., Shidahara, M., Miyake, M., et al. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3035-4 · Cited by 134 · cited 1×
“Moreover, clinical PET studies revealed that these radiotracers were able to differentiate brains of AD subjects from brains of healthy controls [135,136].”
BackgroundMoon, Y., Han, S.-H., & Moon, W.-J. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-151037 · Cited by 132 · cited 2×
“Multiple studies have used quantitative susceptibility mapping (QSM) to quantify the local magnetic susceptibility derived from MRI images caused by deposits containing both Aβ and iron [224,226,227].”
BackgroundTherapeutic strategies for tau mediated neurodegeneration
Yoshiyama, Y., Lee, V. M. Y., & Trojanowski, J. Q. (2013) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-303144 · Cited by 131 · cited 1×
“On the other hand, tau levels slowly increase during the AD continuum with a steep increment approximately eight to nine years before disease onset (Figure 1) [21].”
BackgroundLeuzy, A., Chiotis, K., Hasselbalch, S. G., Rinne, J. O., de Mendonça, A., Otto, M., Lleó, A., Castelo-Branco, M., Santana, I., Johansson, J., et al. (2016) · Brain · doi:10.1093/brain/aww160 · Cited by 131 · cited 1×
“published a paper concerning the increased PiB retention restricted to specific brain regions associated with higher levels of Aβ deposition [96].”
BackgroundPET imaging of synaptic density: A new tool for investigation of neuropsychiatric diseases
Cai, Z., Li, S., Matuskey, D., Nabulsi, N., & Huang, Y. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2018.07.038 · Cited by 131 · cited 2×
“Although these results seem promising, large scale validation of this and other radiotracers is necessary to further exploit the clinical possibilities of SV2A in AD [9].”
BackgroundResultAlzheimer’s disease as oligomeropathy
Ono, K. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2017.08.010 · Cited by 129
Brain metabolic maps in Mild Cognitive Impairment predict heterogeneity of progression to dementia
Cerami, C., Della Rosa, P. A., Magnani, G., Santangelo, R., Marcone, A., Cappa, S. F., & Perani, D. (2015) · NeuroImage: Clinical · doi:10.1016/j.nicl.2014.12.004 · Cited by 127
Hoy, A. R., Ly, M., Carlsson, C. M., Okonkwo, O. C., Zetterberg, H., Blennow, K., Sager, M. A., Asthana, S., Johnson, S. C., Alexander, A. L., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0173982 · Cited by 125
Quantitative susceptibility mapping to evaluate the early stage of Alzheimer's disease
Kim, H.-G., Park, S., Rhee, H. Y., Lee, K. M., Ryu, C.-W., Rhee, S. J., Lee, S. Y., Wang, Y., & Jahng, G.-H. (2017) · NeuroImage: Clinical · doi:10.1016/j.nicl.2017.08.019 · Cited by 125 · cited 2×
“Therefore, the detection of iron with QSM may be of potential aid in imaging Aβ in the early diagnosis of AD [227].”
BackgroundPositron emission tomography in patients with clinically diagnosed Alzheimer's disease.
McGeer, P. L., Kamo, H., Harrop, R., Li, D. K., Tuokko, H. A., McGeer, E. G., Adam, M. J., Ammann, W., Beattie, B. L., & Calne, D. B. (1986) · Europe PMC (PubMed Central) · Cited by 122
Wolk, D. A., Zhang, Z., Boudhar, S., Clark, C. M., Pontecorvo, M. J., & Arnold, S. E. (2012) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-302548 · Cited by 122 · cited 1×
“Florbetapir was the first fluorinated radiotracer and had retention ratios strongly associated with PiB [103,108].”
BackgroundXie, L., Wisse, L. E. M., Pluta, J., de Flores, R., Piskin, V., Manjón, J. V., Wang, H., Das, S. R., Ding, S., Wolk, D. A., et al. (2019) · Human Brain Mapping · doi:10.1002/hbm.24607 · Cited by 121
Sojkova, J., Driscoll, I., Iacono, D., Zhou, Y., Codispoti, K.-E., Kraut, M. A., Ferrucci, L., Pletnikova, O., Mathis, C. A., Klunk, W. E., et al. (2011) · Archives of Neurology · doi:10.1001/archneurol.2010.357 · Cited by 113 · cited 1×
“This pattern was histological confirmed by the comparison of imaging data with immunohistochemical exams post-mortem [97,98].”
PET Quantification of Tau Pathology in Human Brain with 11C-PBB3
Kimura, Y., Ichise, M., Ito, H., Shimada, H., Ikoma, Y., Seki, C., Takano, H., Kitamura, S., Shinotoh, H., Kawamura, K., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.160127 · Cited by 110 · cited 5×
“The compound exhibited up to 50fold higher binding affinity for tau than for Aβ, binds to a wide range of tau isoforms [143] and has affinity for tau at a binding site differently than other radiotracers, which might explain its wide binding range [129].”
BackgroundInfluentialAβ-amyloid and Tau Imaging in Dementia
Villemagne, V. L., Doré, V., Bourgeat, P., Burnham, S. C., Laws, S., Salvado, O., Masters, C. L., & Rowe, C. C. (2017) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2016.09.006 · Cited by 110 · cited 2×
“As mentioned above, it is hypothesized that Aβ burden reaches a plateau as AD progresses [180,184], making longitudinal tracking of Aβ accumulation not the most promising biomarker for disease progression.”
BackgroundIdentification of the Early Stage of Alzheimer's Disease Using Structural MRI and Resting-State fMRI
Hojjati, S. H., Ebrahimzadeh, A., & Babajani-Feremi, A. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00904 · Cited by 108
Devanand, D. P., Mikhno, A., Pelton, G. H., Cuasay, K., Pradhaban, G., Dileep Kumar, J. S., Upton, N., Lai, R., Gunn, R. N., Libri, V., et al. (2010) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988710363715 · Cited by 107 · cited 1×
“In another study, PiB-PET clearly differentiated AD patients from MCI and healthy subjects [95].”
Increased functional connectivity within medial temporal lobe in mild cognitive impairment
Das, S. R., Pluta, J., Mancuso, L., Kliot, D., Orozco, S., Dickerson, B. C., Yushkevich, P. A., & Wolk, D. A. (2013) · Hippocampus · doi:10.1002/hipo.22051 · Cited by 100
Characteristics of Tau and Its Ligands in PET Imaging
Harada, R., Okamura, N., Furumoto, S., Tago, T., Yanai, K., Arai, H., & Kudo, Y. (2016) · Biomolecules · doi:10.3390/biom6010007 · Cited by 100 · cited 3×
“18F-FDDNP 18F-FDDNP is a fluorinated naphthyl-ethylidene derivative and was the first tracer applied in PET imaging of tauopathy in the brain [130].”
BackgroundMethodGray Matter Changes in Parkinson’s and Alzheimer’s Disease and Relation to Cognition
Krajčovičová, L., Klobušiaková, P., & Rektorová, I. (2019) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-019-1006-z · Cited by 100
Using Pittsburgh Compound B for In Vivo PET Imaging of Fibrillar Amyloid-Beta
(2012) · Advances in Pharmacology · doi:10.1016/b978-0-12-394816-8.00002-7 · Cited by 99
In vivo tau imaging: Obstacles and progress
Villemagne, V. L., & Okamura, N. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.04.013 · Cited by 96 · cited 10×
“Second, the i tracellular location of NTFs poses a se nd barri r for the radiotracer to overcome [4,117,127].”
BackgroundInfluentialPropagation of Tau Pathology: Integrating Insights From Postmortem and In Vivo Studies
Vogels, T., Leuzy, A., Cicognola, C., Ashton, N. J., Smolek, T., Novak, M., Blennow, K., Zetterberg, H., Hromadka, T., Zilka, N., et al. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.09.019 · Cited by 95 · cited 2×
“With extensive research into the different spreading patterns across the dementia spectrum, this disadvantage can become an advantage, as heterogeneity contributes to accurate longitudinal monitoring of the different AD types [190,192].”
BackgroundLongitudinal neuroimaging biomarkers differ across Alzheimer’s disease phenotypes
Sintini, I., Graff-Radford, J., Senjem, M. L., Schwarz, C. G., Machulda, M. M., Martin, P. R., Jones, D. T., Boeve, B. F., Knopman, D. S., Kantarci, K., et al. (2020) · Brain · doi:10.1093/brain/awaa155 · Cited by 95
Progressive Tau Accumulation in Alzheimer Disease: 2-Year Follow-up Study
Cho, H., Choi, J. Y., Lee, H. S., Lee, J. H., Ryu, Y. H., Lee, M. S., Jack, C. R., & Lyoo, C. H. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.221697 · Cited by 94 · cited 1×
“, this study reported hierarchical spreading of tau from the entorhinal cortex to other brain regions (Figure 2) [189].”
BackgroundSvedberg, M. M., Hall, H., Hellström‐Lindahl, E., Estrada, S., Guan, Z.-Z., Nordberg, A. K., & Långström, B. (2008) · Neurochemistry International · doi:10.1016/j.neuint.2008.12.016 · Cited by 93 · cited 1×
“Additionally, increasing evidence suggests insoluble Aβ being only a fraction of total Aβ in the brain [101] and a more prominent role of soluble protofibrils in the pathogenesis of Aβ [102].”
Murugan, N. A., Nordberg, A., & Ågren, H. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00093 · Cited by 92 · cited 6×
“The compound exhibited up to 50fold higher binding affinity for tau than for Aβ, binds to a wide range of tau isoforms [143] and has affinity for tau at a binding site differently than other radiotracers, which might explain its wide binding range [129].”
BackgroundMethodInfluentialOno, K., & Tsuji, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030952 · Cited by 92 · cited 1×
“Additionally, increasing evidence suggests insoluble Aβ being only a fraction of total Aβ in the brain [101] and a more prominent role of soluble protofibrils in the pathogenesis of Aβ [102].”
BackgroundHippocampal Damage in the Human Brain after Cardiac Arrest
Fujioka, M., Nishio, K., Miyamoto, S., Hiramatsu, K.-I., Sakaki, T., Okuchi, K., Taoka, T., & Fujioka, S. (2000) · Cerebrovascular Diseases · doi:10.1159/000016018 · Cited by 85 · cited 2×
“Additionally, volume reduction has also been observed after cardiac arrest [49], chronic alcohol abuse [50] and survivors of low birth weight [51].”
BackgroundA Systematic Review of Longitudinal Studies Which Measure Alzheimer’s Disease Biomarkers
Lawrence, E., Vegvari, C., Ower, A., Hadjichrysanthou, C., De Wolf, F., & Anderson, R. M. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-170261 · Cited by 83 · cited 3×
“found that most studies that monitor disease progression have small sample sizes with regularly below a hundred participants, probably due to high costs associated with repeated MRI measures [14].”
BackgroundInfluentialLongitudinal tau-PET uptake and atrophy in atypical Alzheimer's disease
Sintini, I., Martin, P. R., Graff-Radford, J., Senjem, M. L., Schwarz, C. G., Machulda, M. M., Spychalla, A. J., Drubach, D. A., Knopman, D. S., Petersen, R. C., et al. (2019) · NeuroImage: Clinical · doi:10.1016/j.nicl.2019.101823 · Cited by 83 · cited 3×
“Interestingly, the regional patterns of tau accumulation and atrophy differed from one another in atypical AD [126].”
BackgroundLongitudinal neuroanatomical and cognitive progression of posterior cortical atrophy
Firth, N. C., Primativo, S., Marinescu, R.-V., Shakespeare, T. J., Suarez-Gonzalez, A., Lehmann, M., Carton, A., Ocal, D., Pavisic, I., Paterson, R. W., et al. (2019) · Brain · doi:10.1093/brain/awz136 · Cited by 83 · cited 3×
“In similarity with sMRI in the early diagnosis of AD, it is important to note that spatial patterns of atrophy differ per AD subtype [58].”
BackgroundPanegyres, P. K., Rogers, J. M., McCarthy, M., Campbell, A., & Wu, J. S. (2009) · BMC Neurology · doi:10.1186/1471-2377-9-41 · Cited by 81 · cited 3×
“demonstrated that FDG-PET is able to differentiate between different types of dementia up to 95% [60].”
BackgroundMethodInfluentialIshiki, A., Okamura, N., Furukawa, K., Furumoto, S., Harada, R., Tomita, N., Hiraoka, K., Watanuki, S., Ishikawa, Y., Tago, T., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0140311 · Cited by 77 · cited 1×
“performed a longitudinal study into tauopathy with the then novel radiotracer 18F-THK-5117 [186].”
BackgroundWu, X.-L., Piña-Crespo, J., Zhang, Y.-W., Chen, X.-C., & Xu, H.-X. (2017) · Chinese Medical Journal · doi:10.4103/0366-6999.220313 · Cited by 77 · cited 10×
“Second, the i tracellular location of NTFs poses a se nd barri r for the radiotracer to overcome [4,117,127].”
BackgroundInfluentialBrueggen, K., Dyrba, M., Barkhof, F., Hausner, L., Filippi, M., Nestor, P. J., Hauenstein, K., Klöppel, S., Grothe, M. J., Kasper, E., et al. (2015) · Journal of Alzheimer’s Disease · doi:10.3233/jad-150063 · Cited by 75
Longitudinal and cross-sectional structural magnetic resonance imaging correlates of AV-1451 uptake
Das, S. R., Xie, L., Wisse, L. E. M., Ittyerah, R., Tustison, N. J., Dickerson, B. C., Yushkevich, P. A., & Wolk, D. A. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.01.024 · Cited by 72 · cited 1×
“Moreover, the uptake of flortaucipir corresponds well with the expected spatial pattern of tau pathology in the brain of AD subjects (Figure 3) [140,141].”
BackgroundAlzheimer’s Disease Pathologic Cascades: Who Comes First, What Drives What
Swerdlow, R. H. (2012) · Neurotoxicity Research · doi:10.1007/s12640-011-9272-9 · Cited by 66 · cited 1×
“However, this belief is still subject to debate [84,85].”
BackgroundManera, A. L., Dadar, M., Collins, D. L., & Ducharme, S. (2019) · NeuroImage: Clinical · doi:10.1016/j.nicl.2019.102079 · Cited by 65 · cited 1×
“Additionally, data from multiple studies, imaging equipment and research centers can be processed without bias [197].”
BackgroundLee, S., Lee, H., & Kim, K. W. (2020) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.180171 · Cited by 65 · cited 2×
“Moreover, recent study has demonstrated that hippocampal texture predicts conversion from MCI to AD with higher accuracy than the hippocampal volume, although these results have to be validated with histological data [52].”
BackgroundResultImaging endpoints for clinical trials in Alzheimer’s disease
Cash, D. M., Rohrer, J. D., Ryan, N. S., Ourselin, S., & Fox, N. C. (2014) · Alzheimer's Research & Therapy · doi:10.1186/s13195-014-0087-9 · Cited by 62
Yu, E., Liao, Z., Mao, D., Zhang, Q., Ji, G., Li, Y., & Ding, Z. (2017) · Current Alzheimer Research · doi:10.2174/1567205013666161201201000 · Cited by 62
Gong, N., Chan, C., Leung, L., Wong, C., Dibb, R., & Liu, C. (2017) · Human Brain Mapping · doi:10.1002/hbm.23535 · Cited by 61 · cited 1×
“The senile plaques contain primarily neurotoxic amyloid-β (Aβ) [5], whereas NFTs consist of abnormal hyperphosphorylated tau aggregates [6,7].”
BackgroundPeripheral Biomarkers for Early Detection of Alzheimer’s and Parkinson’s Diseases
Htike, T. T., Mishra, S., Kumar, S., Padmanabhan, P., & Gulyás, B. Z. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1151-4 · Cited by 61
Progress of RAGE Molecular Imaging in Alzheimer’s Disease
Kong, Y., Liu, C., Zhou, Y., Qi, J., Zhang, C., Sun, B., Wang, J., & Guan, Y. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00227 · Cited by 61
Variations in cortical thickness with dementia severity in Alzheimer's disease
Im, K., Lee, J. M., Seo, S. W., Yoon, U., Kim, S. T., Kim, Y., Kim, S. I., & Na, D. L. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.03.032 · Cited by 60 · cited 2×
“has linked disease severity to cortical thickness [40], thereby coupling the clinical dementia ranking stages to a level of cortical thinning.”
BackgroundNeuropsychological correlates of whole brain atrophy in Alzheimer's disease
Schott, J. M., Crutch, S. J., Frost, C. D., Warrington, E. K., Rossor, M. N., & Fox, N. C. (2008) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2008.02.015 · Cited by 60 · cited 1×
“Two other studies also investigated the correlation between whole brain atrophy rates and cognitive performance and underlined the finding that whole-brain atrophy is strongly associated with cognitive decline, making cerebral atrophy an interestingly and clinically relevant biomarker for tracking AD progression [148,…”
BackgroundIn Vivo Comparison of Tau Radioligands 18F-THK-5351 and 18F-THK-5317
Betthauser, T. J., Lao, P. J., Murali, D., Barnhart, T. E., Furumoto, S., Okamura, N., Stone, C. K., Johnson, S. C., & Christian, B. T. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.182980 · Cited by 60 · cited 1×
“Additionally, 18FTHK5351 showed higher specific binding to tau-associated regions than 18F-THK5117 [138].”
BackgroundPET Imaging for Early Detection of Alzheimer’s Disease
Bao, W., Jia, H., Finnema, S. J., Cai, Z., Carson, R. E., & Huang, Y. H. (2017) · PET Clinics · doi:10.1016/j.cpet.2017.03.001 · Cited by 59 · cited 6×
“Pyrido−Indole Derivatives 18F−T808 and flortaucipir, also known as 18F-AV-1451 or 18F-T807, are both fluorinated pyrido-indole derivatives with high selectivity for tau over Aβ deposits [4,111].”
BackgroundInfluentialMercier, J., Provins, L., & Valade, A. (2017) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2017.11.003 · Cited by 59 · cited 1×
“18F-UCBJ is a PET radiotracer considered to be sensitive for synaptic loss, because altered uptake of 18F-UCB-J in the gray matter was correlated to altered expression of SV2A and lower synaptic density [219,220].”
BackgroundTopographical Heterogeneity of Alzheimer’s Disease Based on MR Imaging, Tau PET, and Amyloid PET
Jeon, S., Kang, J. M., Seo, S., Jeong, H. J., Funck, T., Lee, S.-Y., Park, K. H., Lee, Y.-B., Yeon, B. K., Ido, T., et al. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00211 · Cited by 59
Fluid and imaging biomarkers for Alzheimer's disease: Where we stand and where to head to
Henriques, A. D., Benedet, A. L., Camargos, E. F., Rosa-Neto, P., & Nóbrega, O. T. (2018) · Experimental Gerontology · doi:10.1016/j.exger.2018.01.002 · Cited by 54 · cited 6×
“It is seen as a robust and reliable biomarker in the in vivo diagnosis of early stages of AD [23,36,43].”
BackgroundInfluentialAmyloid Imaging in Atypical Presentations of Alzheimer’s Disease
Wolk, D. A. (2013) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-013-0412-x · Cited by 53 · cited 1×
“An increasing body of evidence suggests the utility of Aβ-PET to diagnose patients with atypical manifestations of AD, such as posterior cortical atrophy (PCA) and logopenic-variant primary progressive aphasia (LvPPA) [104,116].”
BackgroundShimada, H., Ataka, S., Tomiyama, T., Takechi, H., Mori, H., & Miki, T. (2011) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000330017 · Cited by 50 · cited 1×
“Second, as previously mentioned, PiB has the tendency to only bind to the fibrillar form of Aβ and has low affinity for soluble oligomeric Aβ [104], while it is believed that in some genetic forms of AD, oligomeric Aβ plays a significant role in the disease manifestations [105,106].”
BackgroundData‐driven approaches for tau‐PET imaging biomarkers in Alzheimer's disease
Vogel, J. W., Mattsson, N., Iturria‐Medina, Y., Strandberg, O. T., Schöll, M., Dansereau, C. L., Villeneuve, S., van der Flier, W. M., Scheltens, P., Bellec, P., et al. (2018) · Human Brain Mapping · doi:10.1002/hbm.24401 · Cited by 50 · cited 1×
“Moreover, data-driven analysis of tau PET images identified spatial patterns of radiotracer 18F-AV1451 signal clusters compared to pathology-based methods, suggesting an advantage for data-driven methods in evaluating radiotracer data [201].”
MethodThe development of effective biomarkers for Alzheimer's disease: a review
Henry, M. S., Passmore, A. P., Todd, S., McGuinness, B., Craig, D., & Johnston, J. A. (2013) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.3829 · Cited by 49 · cited 8×
“These techniques focused on t neuronal injury and degeneration aspects of AD [1].”
BackgroundMethodInfluentialGunes, A. S., Demirci, S., Tök, L., Tök, Ö., & Demirci, S. (2015) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-1405-114 · Cited by 47
Kim, S. H., Seo, S. W., Yoon, D. S., Chin, J., Lee, B. H., Cheong, H., Han, S., & Na, D. L. (2010) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000278422 · Cited by 46 · cited 1×
“With this discrepancy in mind, another research project focused on investigating differences in hypometabolism patterns and neuropsychological characteristics between early and late MCI [160].”
BackgroundCabrera DeBuc, D., Gaca-Wysocka, M., Grzybowski, A., & Kanclerz, P. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8070996 · Cited by 46
Shokouhi, S., Mckay, J. W., Baker, S. L., Kang, H., Brill, A. B., Gwirtsman, H. E., Riddle, W. R., Claassen, D. O., Rogers, B. P., & Initiative, A. D. N. (2016) · Alzheimer s Research & Therapy · doi:10.1186/s13195-016-0172-3 · Cited by 45 · cited 2×
“However, multiple studies question the reliability of the cer bellum a ref rence region for normalization in longitudinal Aβ deposition, si ce it can affect the quantitative outcome in these longitudinal studies and lead to additional variability [182].”
BackgroundResult
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Pathogenesis of Alzheimer’s Disease
Rostagno, A. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010107 · Cited by 383
“The manuscript discussed the value of using radiotracers to assess hippocampal volume, hypometabolism in temporoparietal brain regions, and Aβ and Tau accumulation, emphasizing their limitations regarding specificity, reliability, and sensitivity [18].”
BackgroundThe Expanding Burden of Neurodegenerative Diseases: An Unmet Medical and Social Need
Wang, S., Jiang, Y., Yang, A., Meng, F., & Zhang, J. (2024) · Aging and Disease · doi:10.14336/ad.2024.1071 · Cited by 264
Kale, M., Wankhede, N., Pawar, R., Ballal, S., Kumawat, R., Goswami, M., Khalid, M., Taksande, B., Upaganlawar, A., Umekar, M., et al. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102497 · Cited by 183
Alzheimer’s Disease Detection Using Deep Learning on Neuroimaging: A Systematic Review
Alsubaie, M. G., Luo, S., & Shaukat, K. (2024) · Machine Learning and Knowledge Extraction · doi:10.3390/make6010024 · Cited by 183
Metadata
- Authors
- van Oostveen, W. M., & de Lange, E. C. M.
- Affiliations
- Faculty of Science, Leiden University, Einsteinweg 55, 2333 CC Leiden, The Netherlands
- Division of Systems Biomedicine and Pharmacology, Leiden Academic Centre of Drug Research, Leiden University, Einsteinweg 55, 2333 CC Leiden, The Netherlands
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-02-20
- Volume
- 22
- Issue
- 4
- Pages
- 2110
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC7924338
- OpenAlex
- W3131910442
- Cited by
- 297
- References
- 232
- Citations by year
- 2026: 47 · 2025: 84 · 2024: 75 · 2023: 55 · 2022: 24 · 2021: 11
- FWCI
- 7.53
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, cc-by)
- Leiden Repository (Leiden University) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- Alzheimer's disease, neuroimaging biomarkers, early diagnosis, longitudinal disease monitoring, amyloid PET, hippocampal atrophy, hypometabolism, glucose uptake, neurodegeneration, disease-modifying therapy
- MeSH terms
- Alzheimer Disease, Amyloid, Humans, Longitudinal Studies, Biomarkers, Early Diagnosis, Neuroimaging
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.